ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.

VTGN VistaGen Therapeutics Inc

4,55
0,14 (3,17%)
04 Mai 2024 - Geschlossen
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
VistaGen Therapeutics Inc VTGN NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
0,14 3,17% 4,55 06:00:08
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
4,47 4,31 4,55 4,50 4,41
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
25.4.202414:30BWVistagen Announces Positive Results from Phase 2A Pilot..
09.4.202414:30BWVistagen to Present at the 2024 Anxiety and Depression..
01.4.202414:30BWVistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol..
11.3.202413:30BWVistagen to Present at Stifel 2024 Virtual CNS Days
07.3.202400:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07.3.202400:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07.3.202400:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07.3.202400:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01.3.202406:15EDGAR2Form EFFECT - Notice of Effectiveness
28.2.202414:30BWVistagen to Present at TD Cowen 44th Annual Health Care..
15.2.202400:18EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14.2.202422:51EDGAR2Form SC 13G - Statement of acquisition of beneficial..
14.2.202414:56EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
13.2.202422:52EDGAR2Form S-3 - Registration statement under Securities Act of..
13.2.202422:33EDGAR2Form 8-K - Current report
13.2.202422:25EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13.2.202422:20BWVistagen Reports Fiscal 2024 Third Quarter Financial Results..
06.2.202414:30BWVistagen to Report Fiscal Year 2024 Third Quarter Financial..
03.1.202423:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03.1.202423:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03.1.202423:09EDGAR2Form 8-K - Current report
27.12.202314:30BWVistagen Receives Notice from European Patent Office of..
09.11.202322:44EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09.11.202322:42EDGAR2Form 8-K - Current report
09.11.202322:30BWVistagen Provides Corporate Update and Reports Fiscal 2024..
08.11.202314:30BWVistagen to Present at Stifel 2023 Healthcare Conference
07.11.202314:30BWVistagen to Present Positive Fasedienol Phase 3 Data and..
07.11.202303:46EDGAR2Form 8-K/A - Current report: [Amend]
06.11.202322:27EDGAR2Form 8-K - Current report
06.11.202314:00BWVistagen To Report Second Quarter Financial Results and Host..
04.11.202301:14EDGAR2Form 3 - Initial statement of beneficial ownership of..
26.10.202322:13EDGAR2Form 8-K - Current report
16.10.202322:37EDGAR2Form SC 13G - Statement of acquisition of beneficial..
16.10.202322:01EDGAR2Form SC 13G - Statement of acquisition of beneficial..
06.10.202322:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06.10.202322:05EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
05.10.202322:47EDGAR2Form SC 13G - Statement of acquisition of beneficial..
05.10.202314:30BWVistagen to Present at Jefferies Inaugural Biotech CNS/Neuro..
04.10.202322:07EDGAR2Form 8-K - Current report
03.10.202322:40EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
02.10.202313:30BWVistagen Announces Pricing of $100 Million Underwritten..
02.10.202313:15EDGAR2Form 8-K - Current report
29.9.202322:26EDGAR2Form 8-K - Current report
12.9.202314:30BWVistagen Announces Positive Results from Exploratory Phase..
08.9.202323:27EDGAR2Form 8-K - Current report
05.9.202315:00BWVistagen and Fuji Enter Exclusive Negotiation Agreement for..
23.8.202319:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23.8.202319:08EDGAR2Form 3 - Initial statement of beneficial ownership of..
22.8.202314:40EDGAR2Form 8-K - Current report
22.8.202314:30BWVistagen Appoints Cindy Anderson as Chief Financial Officer

Kürzlich von Ihnen besucht

Delayed Upgrade Clock